Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q3 2025 Earnings Presentation
13 slides from Bionano Genomics's earnings presentation, Nov 13, 2025
Slide 1: Q3'25 Financial Results Webcast & Call
Q3’25 Financial Results Webcast & Call November 13, 2025
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation
Slide 3: OGM consolidates legacy cytogenetics into a single digital platform
OGM consolidates legacy cytogenetics into a single digital platform for structural variant detection and analysis Cytogenetics Molecular Anatomic Pathology/Clinical Pathology H&E Karyotyping FISH CMA RNA (Transcriptomics) DNA (Sequencing) Flow cytometry/Mass spectrometry staining Current State (SOC)
Slide 4: Strategic pillars and key imperatives for 2025
Strategic pillars and key imperatives for 2025 Support & sustain the Drive utilization through installed base of routine adoption of VIA software OGM & VIA software users across routine OGM users & facilitate menu expansion Improve profitability Build support needed for OGM reimbursement & and scala
Slide 5: Third quarter 2025 financial results
Revenue: $7.4M Third quarter 2025 financial results (21% vs. Q3’24); 10 450 (12% vs. Q3’24 core revenue1) 371 379 378 384 400 Flowcells (FCs) sold: 8,390 8 363 368 (+7% vs. Q3’24) 347 350 326 301 New OGM installations: 7 (YTD: 23) 6 300 281 259 240 250 4 217 8.7 8.2 OGM installed base: 384 196 7.2 7
Slide 6: Consumable and software revenue is growing, in line with new strategy to focus on routine users
Consumable and software revenue is growing, in line with new strategy to focus on routine users Q3 2025 YTD 2025 22,249 22,617 Flowcells Sold 7,835 8,390 576 3,648 2,709 492 In connection to new +7% customer sales +6% 7,343 7,814 18,601 19,908 To existing customer base Q3 2024 Q3 2025 YTD 2024 YTD 2
Slide 7: Stabilization of gross margin and cost structure following substantial improvements over the last two years
Stabilization of gross margin and cost structure following substantial improvements over the last two years Reduced non-GAAP operating expenses1 Improved non-GAAP gross margin1 to 46% by 40% y/y in Q3 2025 in Q3 2025, compared to non-GAAP core gross margin of 31%2 in Q3 2024 Non-GAAP Operating Expen
Slide 8: Growing number of publications and published human clinical research genomes
Growing number of publications and published human clinical research genomes as researchers increasingly leverage OGM 97 new publications in Q3 2025 (+10% y/y) 841 human clinical research genomes published across a range of applications in Q3 2025 (+84% y/y), reaching nearly 11,500 in total 359 12,0
Slide 9: Strong momentum in key geographies and growing interest in new regions
Strong momentum in key geographies and growing interest in new regions Effectiveness of OGM New MD Anderson Multiple studies published highlighted through nine publication shows how in Methods in Molecular studies at ASHG, including OGM can overcome key Biology highlight OGM oral presentations and l
Slide 10: CMS posted preliminary payment determination for new Category I CPT code covering use of OGM
CMS posted preliminary payment determination for new Category I CPT code covering use of OGM for constitutional genetic disorders AMA CPT Code for OGM A new Category I CPT1 code for the use of OGM in cytogenomic genome-wide analysis for Current Code # 81354 constitutional genetic disorders was estab
Slide 11: Reiterating full year 2025 guidance and raising expectations for new OGM installations
Reiterating full year 2025 guidance and raising expectations for new OGM installations Reiterating FY’25 revenue: $26 – $30M Expecting FY’25 new OGM installations to surpass 25 systems vs. prior expectations of 20 – 25 systems Initiating Q4’25 revenue: $7.5 – $7.9M © Copyright 2025 Bionano Genomics,
Slide 12: Thank you.
— Thank you.
Slide 13: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) 1 1. For all periods through Q3 2024, non-GAAP gross margin includes non-GAAP gross margin for discontinued services © Copyright 2025 Bionano Genomics, Inc. 13